BRPI0608089A2 - composto, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo - Google Patents

composto, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo

Info

Publication number
BRPI0608089A2
BRPI0608089A2 BRPI0608089-8A BRPI0608089A BRPI0608089A2 BR PI0608089 A2 BRPI0608089 A2 BR PI0608089A2 BR PI0608089 A BRPI0608089 A BR PI0608089A BR PI0608089 A2 BRPI0608089 A2 BR PI0608089A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
treatment
Prior art date
Application number
BRPI0608089-8A
Other languages
English (en)
Inventor
Kurt Hilpert
Olivier Houille
Francis Hubler
Emmanuel Meyer
Eva Caroff
Heinz Fretz
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0608089A2 publication Critical patent/BRPI0608089A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO OU DE UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO. A invenção diz respeito aos derivados de 4-aminocarbonilpirimidina e seu uso como antagonistas do receptor de P2Y12 no tratamento e/ou prevenção e/ou tratamento de doenças ou condições vasculares periféricas, vasculares visc erais, hepáticas e renais, cardiovasculares e cerebrovasculares associadas com agregação de plaqueta, incluindo trombose em seres humanos e outros ir amíferos.
BRPI0608089-8A 2005-04-28 2006-04-27 composto, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo BRPI0608089A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2005004578 2005-04-28
IB2005053711 2005-11-10
PCT/IB2006/051318 WO2006114774A2 (en) 2005-04-28 2006-04-27 Pyrimidine derivatives and their use as p2y12 receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0608089A2 true BRPI0608089A2 (pt) 2009-11-10

Family

ID=37075078

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608089-8A BRPI0608089A2 (pt) 2005-04-28 2006-04-27 composto, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo

Country Status (18)

Country Link
US (1) US8048881B2 (pt)
EP (1) EP1893634B1 (pt)
JP (1) JP4955658B2 (pt)
KR (1) KR101310016B1 (pt)
CN (1) CN101166756A (pt)
AR (1) AR056992A1 (pt)
AT (1) ATE538130T1 (pt)
AU (1) AU2006241260A1 (pt)
BR (1) BRPI0608089A2 (pt)
CA (1) CA2604967C (pt)
ES (1) ES2377337T3 (pt)
IL (1) IL186939A0 (pt)
MX (1) MX2007013436A (pt)
NO (1) NO20076094L (pt)
NZ (1) NZ563584A (pt)
RU (1) RU2410393C2 (pt)
TW (1) TW200640877A (pt)
WO (1) WO2006114774A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210635A1 (en) * 2006-03-29 2010-08-19 Takeda Pharmaceutical Company Limited Renin inhibitors
CL2007002920A1 (es) * 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) * 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
CA2684644A1 (en) * 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
RU2483072C2 (ru) * 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
EP2238128B1 (en) * 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
WO2009110985A2 (en) 2008-02-29 2009-09-11 Renovis, Inc. Amide compounds, compositions and uses thereof
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) * 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
JP5341069B2 (ja) * 2008-04-22 2013-11-13 第一三共株式会社 ５−ヒドロキシピリミジン−４−カルボキサミド化合物
US20110237578A1 (en) * 2008-09-18 2011-09-29 Zhi-Liang Wei Amide compounds, compositions and uses thereof
KR101114503B1 (ko) * 2008-12-04 2012-02-15 지에스건설 주식회사 부유물 수거장치
MX2011010200A (es) * 2009-04-08 2011-10-14 Actelion Pharmaceuticals Ltd 6-(3-aza-biciclo[3.1.0]hex-3-il)-2fenil-pirimidinas como antagonistas del receptor de adenosina 5'-difosfato (adp).
JP5536876B2 (ja) * 2009-04-22 2014-07-02 アクテリオン ファーマシューティカルズ リミテッド チアゾール誘導体及びｐ２ｙ１２受容体拮抗剤としてのそれらの使用
JP5597202B2 (ja) 2009-08-28 2014-10-01 第一三共株式会社 ３−（ビアリールオキシ）プロピオン酸誘導体
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
US9163008B2 (en) * 2011-09-02 2015-10-20 Purdue Pharma, L.P. Pyrimidines as sodium channel blockers
CN109715639B (zh) 2016-09-22 2022-04-19 爱杜西亚药品有限公司 结晶形式
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
CN112500354A (zh) * 2020-12-08 2021-03-16 烟台凯博医药科技有限公司 一种4-氯-6-环丙基嘧啶-5-胺的合成方法
WO2025133948A1 (en) 2023-12-21 2025-06-26 Pfizer Inc. Acetyl coa-carboxylase (acc) inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) * 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
RU2213744C1 (ru) * 2002-06-27 2003-10-10 Институт органической химии им. Н.Д. Зелинского РАН ПРОИЗВОДНЫЕ АНТРА[2,1-d]ИЗОТИАЗОЛ-3,6,11-ТРИОНА
CN1747732A (zh) 2002-12-11 2006-03-15 舍林股份公司 作为血小板腺苷二磷酸受体拮抗剂的2－氨基羰基喹啉化合物
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
RU2483072C2 (ru) 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
MX2011010200A (es) 2009-04-08 2011-10-14 Actelion Pharmaceuticals Ltd 6-(3-aza-biciclo[3.1.0]hex-3-il)-2fenil-pirimidinas como antagonistas del receptor de adenosina 5'-difosfato (adp).
JP5536876B2 (ja) 2009-04-22 2014-07-02 アクテリオン ファーマシューティカルズ リミテッド チアゾール誘導体及びｐ２ｙ１２受容体拮抗剤としてのそれらの使用

Also Published As

Publication number Publication date
NO20076094L (no) 2008-01-25
KR101310016B1 (ko) 2013-09-30
IL186939A0 (en) 2008-02-09
CN101166756A (zh) 2008-04-23
US20080194576A1 (en) 2008-08-14
JP4955658B2 (ja) 2012-06-20
AR056992A1 (es) 2007-11-07
ATE538130T1 (de) 2012-01-15
EP1893634A2 (en) 2008-03-05
CA2604967C (en) 2014-04-01
WO2006114774A3 (en) 2007-02-08
EP1893634B1 (en) 2011-12-21
JP2008539224A (ja) 2008-11-13
AU2006241260A1 (en) 2006-11-02
TW200640877A (en) 2006-12-01
RU2410393C2 (ru) 2011-01-27
RU2007143880A (ru) 2009-06-10
ES2377337T3 (es) 2012-03-26
MX2007013436A (es) 2008-01-16
NZ563584A (en) 2011-03-31
WO2006114774A2 (en) 2006-11-02
KR20080004608A (ko) 2008-01-09
CA2604967A1 (en) 2006-11-02
US8048881B2 (en) 2011-11-01

Similar Documents

Publication Publication Date Title
BRPI0819696A8 (pt) Compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
CY1114148T1 (el) Γεφυρωμενες δικυκλικες αρυλο- και γεφυρωμενες δικυκλικες etepoapyλo-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις toy axl
BRPI0720178A2 (pt) Derivados de 2,3-di-hidroimidazo[1,2-c]quinazolina substituída úteis para tratar distúrbios e doenças hiperproliferativos associados com angiogênese
EA200900044A1 (ru) Замещенные производные 1,3-дифенилпропана, получение и их применение
UY30015A1 (es) Combinación de antagonista de actividad biológica de angiopoyetina-2 y antagonista de actividad biológica de vegf-a y/o kdr y/o flt1, composiciones farmacéuticas y aplicaciones
IL189499A (en) Use of 2,4-diaminopyrimidines or 4-aminopyrimidines for the preparation of a medicament for the treatment of a respiratory disease mediated by a p2x3 or p2x2/3 receptor antagonist
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
EA201070841A1 (ru) НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
NO20076094L (no) Pyrimidine derivatives and their use as p2y12 receptor antagonists
MX2009003724A (es) Derivados de 2-aminocarbonil-piridina.
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
WO2008012470A3 (fr) Derives d'imidazolones substitues, preparation et utilisations
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
EA200802332A1 (ru) Пирролопиримидины и их применение
CL2007003472A1 (es) Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie
EP2197858A4 (en) 1,3,5-TRIAZIN-2,4,6-TRIAMIN COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT, AND PHARMACEUTICAL COMPOSITION THEREWITH
BRPI0921097A2 (pt) composto derivado de pirazol-3 carboxamida com atividade de antagonista de receptor 5-ht2b, agente preventivo ou terapêutico, composição farmacêutica e uso do composto ou seu sal farmaceuticamente aceitável e método ou prevenção ou tratamento.
WO2008050301A3 (en) 2- phenyl- 6-aminocarbonyl- pyrimidine derivatives and their use as p2y12 receptor antagonists
TW200801022A (en) Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
EA200870421A1 (ru) Димеры производных артемизинина, их получение и их применение в терапии
BRPI0820838B8 (pt) derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso como antagonistas do receptor purinérgico p2x3 e/ou p2x2/3
MA32277B1 (fr) Derives de 2-phenyl-4- cyclopropyl-pyrimidine
BRPI0917245B8 (pt) compostos derivados de isoquinolinona e sua composição farmacêutica
BRPI0911678B8 (pt) maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2211 DE 21/05/2013.